Cohen & Steers, Inc. (CNS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$70.54
Price Target
$76.00
Target Range
$76.00 — $76.00
Analyst Rating
Sell
Forward P/E20.6x
Trailing P/E23.8x
Forward PEG16.39
Implied Growth+7.4%
Median Target$76.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$76
+7.7%
Consensus
$76
+7.7%
Bull Case
$76
+7.7%
Valuation Model TargetsConfidence: 43/100
Bear$38
Base$75
Bull$104
CNS Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Cohen & Steers, Inc. (CNS) has a Wall Street consensus price target of $76.00, based on estimates from 13 covering analysts. With the stock currently trading at $70.54, this represents a potential upside of +7.7%. The company has a market capitalization of $3.60B.
Analyst price targets range from a low of $76.00 to a high of $76.00, representing a 0% spread in expectations. The median target of $76.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Sell, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 5 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CNS trades at a trailing P/E of 23.8x and forward P/E of 20.6x. The forward PEG ratio of 16.39 reflects a premium valuation. Analysts expect EPS to grow +7.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $75.22, with bear and bull scenarios of $38.37 and $104.40 respectively. Model confidence stands at 43/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Financial Services stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+9.2%
Avg Forward P/E10.3x
Peers with Coverage7 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 VRTSVirtus Investment Partners, Inc. | $960M | $143.41 | $163.00 | +13.7% | Hold | 5.6x | 11 |
 VCTRVictory Capital Holdings, Inc. | $5.3B | $82.29 | $78.00 | -5.2% | Buy | 12.0x | 13 |
 DHILDiamond Hill Investment Group, Inc. | $473M | $174.99 | — | — | — | 9.5x | — |
 GROWU.S. Global Investors, Inc. | $35M | $2.62 | — | — | — | — | — |
 HNNAHennessy Advisors, Inc. | $78M | $9.91 | — | — | — | — | — |
 BENFranklin Resources, Inc. | $16.2B | $31.16 | $28.75 | -7.7% | Hold | 11.4x | 27 |
 IVZInvesco Ltd. | $12.2B | $27.35 | $29.72 | +8.7% | Hold | 10.6x | 28 |
 AMGAffiliated Managers Group, Inc. | $8.2B | $306.02 | $331.50 | +8.3% | Buy | 9.2x | 12 |
 APAMArtisan Partners Asset Management Inc. | $2.7B | $37.84 | $40.00 | +5.7% | Hold | 9.9x | 15 |
 MORNMorningstar, Inc. | $6.4B | $167.66 | $236.50 | +41.1% | Hold | 14.1x | 6 |
Upside Potential Comparison
MORNVRTSIVZAMGAPAMVCTRBENSee CNS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNS vs BRK-A
Side-by-side business, growth, and profitability comparison vs Berkshire Hathaway Inc..
Start ComparisonCNS — Frequently Asked Questions
Quick answers to the most common questions about buying CNS stock.
What is the CNS stock price target for 2026?
The consensus price target for CNS is $76, close to the current price of $70.54 (7.7% implied move). Based on 13 analyst estimates, the stock appears fairly valued near current levels.
Is CNS a buy, sell, or hold?
CNS has a consensus rating of "Sell" based on 13 Wall Street analysts. The rating breakdown is leaning bearish, with 5 Sell/Strong Sell ratings. The consensus 12-month price target of $76 implies 7.7% upside from current levels.
Is CNS stock overvalued or undervalued?
CNS trades at a forward P/E of 20.6257x, representing a moderate valuation. With analysts targeting $76 (7.7% implied move), the stock appears reasonably valued with upside.
How high can CNS stock go?
The most bullish Wall Street analyst has a price target of $76 for CNS, while the most conservative target is $76. The consensus of $76 represents the median expectation. Our quantitative valuation model projects a bull case target of $104 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover CNS stock?
CNS is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CNS stock forecast?
The 12-month CNS stock forecast based on 13 Wall Street analysts shows a consensus price target of $76, with estimates ranging from $76 (bear case) to $76 (bull case). The median consensus rating is "Sell". Our proprietary valuation model produces a base case fair value of $75, with bear/bull scenarios of $38/$104.
What is CNS's fair value based on fundamentals?
Our quantitative valuation model calculates CNS's fair value at $75 (base case), with a bear case of $38 and bull case of $104. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.
What is CNS's forward P/E ratio?
CNS trades at a forward P/E ratio of 20.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 23.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CNS stock?
CNS appears fairly valued according to analysts, with a "Sell" rating and minimal upside to the $76 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CNS price targets vary so much?
CNS analyst price targets range from $76 to $76, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $76 consensus represents the middle ground. Our model's $38-$104 range provides an independent fundamental perspective.